The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the prognostic/predictive role of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients treated with first-line chemotherapy.
Helena Linardou
No relevant relationships to disclose
Paris A. Kosmidis
No relevant relationships to disclose
Vassiliki Kotoula
No relevant relationships to disclose
Vasilios Karavasilis
No relevant relationships to disclose
Anastasia G Eleftheraki
No relevant relationships to disclose
Georgios Lazaridis
No relevant relationships to disclose
Emily Daskalaki
No relevant relationships to disclose
Sotiris Lakis
No relevant relationships to disclose
Elpida Charalambous
No relevant relationships to disclose
Epaminontas Samantas
No relevant relationships to disclose
Dimitrios G. Pectasides
No relevant relationships to disclose
Dimitris Bafaloukos
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose